MedTrace Logo

Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

NCT04615364 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-05-23

No results posted yet for this study

Summary

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries. A promising strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy was implemented in Nouméa as part of the World Mosquito Program. This intervention will modify the epidemiological profile of arboviruses in New Caledonia.

Epidemiological surveillance of arboviruses requires molecular characterization of the virus contained in the serum obtained from the blood collected from patients. This molecular characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the construction of phylogenetic trees.

In the context of the implementation of the World Mosquito Program in Nouméa, the investigators plan to follow the molecular evolution of arboviruses, over the period preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a period of 5 years. following the releases.

At the same time, the virus can be isolated by cell culture techniques and in vitro infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.

Conditions

  • Arbovirus Infections
  • Dengue
  • Zika
  • Chikungunya

Sponsors & Collaborators

  • Institut Pasteur de Nouvelle-Calédonie

    collaborator UNKNOWN

  • Centre Hospitalier Territorial de Nouvelle-Calédonie

    collaborator OTHER

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Myrielle Dupont-Rouzeyrol, PhD · Institut Pasteur de Nouvelle-Calédonie

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2025-07-17
Completion
2025-07-17

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615364 on ClinicalTrials.gov